Your browser doesn't support javascript.
loading
Diagnostic methods for primary vitreoretinal lymphoma: A systematic review.
Huang, Ryan S; Mihalache, Andrew; Popovic, Marko M; Cruz-Pimentel, Miguel; Pandya, Bhadra U; Muni, Rajeev H; Kertes, Peter J.
Afiliação
  • Huang RS; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Mihalache A; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Popovic MM; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
  • Cruz-Pimentel M; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
  • Pandya BU; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Muni RH; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada.
  • Kertes PJ; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address: peter.kertes@sunnybrook.ca.
Surv Ophthalmol ; 69(3): 456-464, 2024.
Article em En | MEDLINE | ID: mdl-38163550
ABSTRACT
Primary vitreoretinal lymphoma is a potentially aggressive intraocular malignancy with poor systemic prognosis and sometimes significant diagnostic delays as it may masquerade as chronic uveitis. Despite the variety of diagnostic techniques, it is unclear which modality is most accurate in the diagnosis of PVRL. A systematic literature search was conducted on Ovid MEDLINE, EMBASE and the Cochrane Controlled Register of Trials for studies published between January, 2000, and June, 2023. Randomized controlled trials (RCTs) reporting on the following diagnostic tools used to diagnose patients with PVRL were included cytology, flow cytometry, MYD88 L265P mutation, CD79B mutation, interleukin 10/interleukin-6 (IL-10/IL-6) ratio, polymerase chain reaction (PCR) for monoclonal immunoglobulin heavy chain (IgH) and immunoglobulin kappa light chain (IgK) rearrangements, and imaging findings. The aggregated sensitivity of each diagnostic modality was reported and compared using the chi-squared (χ2) test. A total of 662 eyes from 29 retrospective studies reporting on patients diagnosed with PVRL were included. An IL-10/IL-6 ratio greater than 1 had the highest sensitivity (89.39%, n = 278/311 eyes, n = 16 studies) for PVRL, where the sensitivity was not significantly different when only vitreous samples were drawn (88.89%, n = 232/261 eyes, n = 13 studies) compared to aqueous samples (83.33%, n = 20/24, n = 2) (p = 0.42). Flow cytometry of vitreous samples gave a positive result in 66/75 eyes (88.00%, n = 6 studies) with PVRL, and monoclonal IgH rearrangements on PCR gave a positive result in 354/416 eyes (85.10%, n = 20 studies) with PVRL. MYD88 L265P and CD79B mutation analysis performed poorly, yielding a positive result in 63/90 eyes (70.00%, n = 8 studies) with PVRL, and 20/57 eyes (35.09%, n = 4 studies) with PVRL, respectively. Overall, our systematic review found that an IL-10/IL-6 ratio greater or equal to one may provide the highest sensitivity in identifying patients with PVRL. Future studies are needed to employ multiple diagnostic tools to aid in the detection of PVRL and to further establish nuanced guidelines when determining the optimal diagnostic tool to use in diverse patient populations.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Corpo Vítreo / Neoplasias da Retina Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Surv Ophthalmol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Corpo Vítreo / Neoplasias da Retina Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Surv Ophthalmol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá